肿瘤研究与临床最新文献

{"title":"Value of human mitochondrial transcription termination factor 3 and forkhead box protein 3 in predicting the prognosis of non-small cell lung cancer","authors":"D. Su, Dongbo Li, Weiwei Zhang, Jingxu Cao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.002","url":null,"abstract":"Objective \u0000To explore the prognostic value of human mitochondrial transcription termination factor 3 (hMTERF3) and forkhead box protein 3 (Foxp3) in non-small cell lung cancer (NSCLC). \u0000 \u0000 \u0000Methods \u0000The clinical data of 88 patients with NSCLC who were admitted to the Third Medical Center of PLA General Hospital from March 2017 to March 2018 were retrospectively analyzed. All patients were diagnosed by pathological puncture. The patients were followed-up by telephone for 12 months, and according to the prognosis, the patients were divided into good prognosis group and poor prognosis group. The pathological tissues were taken from all patients, and the expressions of hMTERF3 and Foxp3 proteins were detected by immunohistochemistry. The expressions of hMTERF3 and Foxp3 in the good prognosis group and the poor prognosis group were compared. Logistic regression model was used to analyze the risk factors of poor prognosis in patients with NSCLC. \u0000 \u0000 \u0000Results \u0000Of 88 patients, 61 patients (69.3%) had good prognosis and 27 patients (30.7%) had poor prognosis. The positive expression rate of hMTERF3 in the good prognosis group was 57.4% (35/61), which was significantly lower than that in the poor prognosis group (81.5%, 22/27) (χ 2= 4.766, P= 0.029). The positive expression rate of Foxp3 in the good prognosis group was 55.7% (34/61), which was significantly lower than that in the poor prognosis group (85.2%, 23/27) (χ 2= 7.113, P= 0.008). The proportions of patients with medium and high differentiation or stage Ⅰ- Ⅱ in the good prognosis group were 82.0% (50/61) and 68.8% (42/61), respectively, which were significantly higher than those in the poor prognosis group [48.15% (13/27) and 25.93% (7/27)] (both P < 0.05). Logistic regression analysis showed that the poor differentiation, stage Ⅲ-Ⅳ, hMTERF3-positive and Foxp3-positive were the risk factors for poor prognosis in NSCLC patients (all P < 0.05). \u0000 \u0000 \u0000Conclusions \u0000The positive expression rates of hMTERF3 and Foxp3 in patients with good prognosis are lower. The hMTERF3-positive and Foxp3-positive are risk factors for poor prognosis in NSCLC patients. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Mitochondrial proteins; Forkhead transcription factors; Human mitochondrial transcription termination factor 3; Forkhead box protein 3; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"6-10"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47027088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of anesthesia depth on stress response during single-lung ventilation in thoracic surgery","authors":"Xiao-yan Wang, T. Xing, G. Han, Yi Liu, Xiaoli An","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.003","url":null,"abstract":"Objective \u0000To study the effects of different anesthesia depths on stress response during single-lung ventilation in patients with thoracoscopic lobectomy. \u0000 \u0000 \u0000Methods \u0000Sixty patients selected for elective thoracoscopic lobectomy in the Second Hospital of Shanxi Medical University from September 2018 to May 2019 were randomly divided into three groups according to the digital random table method, with 20 patients in each group. Group A maintained deep anesthesia with the bispectral index (BIS) 36-45, group B maintained moderate anesthesia with BIS 46-55, and group C did not undergo BIS monitoring. The changes of heart rate, mean arterial pressure (MAP), stress indexes cortisol and blood glucose before anesthesia induction (T0), immediately after one-lung ventilation (T1), 60 min after one-lung ventilation (T2) and immediately after skin suture (T3) in the three groups were compared. \u0000 \u0000 \u0000Results \u0000The concentration of blood glucose in group A at T1, T2 and T3 was (5.28±0.49) mmol/L, (5.34±0.49) mmol/L and (5.40±0.47) mmol/L, and the cortisol was (142.75±31.45) ng/ml, (181.36±19.62) ng/ml and (153.81±33.92) ng/ml; the blood glucose in group B was (5.63±0.35) mmol/L, (6.06±0.19) mmol/L and (5.79±0.44) mmol/L, and the cortisol was (168.45±31.16) ng/ml, (171.09±25.28) ng/ml and (159.39±18.77) ng/ml; the blood glucose in group C was (6.35±0.56) mmol/L, (7.04±0.26) mmol/L and (6.17±0.54) mmol/L, and the cortisol was (191.13±46.00) ng/ml, (283.25±30.07) ng/ml and (183.01±19.71) ng/ml, respectively. The blood glucose and cortisol levels in group C at T1, T2 and T3 were higher than those in group A and group B (all P < 0.05). The MAP in group A at T1, T2 and T3 were (69±5) mmHg (1 mmHg= 0.133 kPa), (67±6) mmHg and (75±7) mmHg, respectively, and group B was (80±8) mmHg, (79±4) mmHg and (84±9) mmHg, the differences between the two groups were statistically significant (all P < 0.05). There was significant difference in cortisol between group A and group B at T1 (P < 0.05). The heart rate and MAP at T1, T2 and T3 in group A and group C were significantly different from those at T0 (all P < 0.05). The heart rate and MAP at T1 and T2 in groups B were significantly different from those at T0 (all P < 0.05). \u0000 \u0000 \u0000Conclusion \u0000BIS anesthesia depth monitoring should be performed during single-lung ventilation in thoracic surgery, and BIS should be maintained at 46-55, which can not only inhibit the stress response but also have a slight effect on hemodynamics. \u0000 \u0000 \u0000Key words: \u0000Surgical procedures, operative; Monitoriry, intraoperative; Stress; Depth of anesthesia; Bispectral index monitoring","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"11-15"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47321753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy observation of bevacizumab for treatment of lung adenocarcinoma patients with brain metastasis and refractory cerebral edema","authors":"Chao Xiao, Ran Li, Qingshan Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.010","url":null,"abstract":"目的 \u0000探讨贝伐珠单抗治疗肺腺癌脑转移瘤伴难治性脑水肿的效果及对血清血管内皮生长因子（VEGF）的影响。 \u0000 \u0000 \u0000方法 \u0000回顾性分析2015年7月至2018年12月青岛市中心医院收治的25例肺腺癌脑转移伴难治性脑水肿患者的临床资料，既往经甘露醇联合糖皮质激素脱水降颅压治疗无效。患者分为单用贝伐珠单抗组和联用贝伐珠单抗组。给予贝伐珠单抗（5 mg/kg）治疗后评估患者临床症状、功能状态评分（KPS）、瘤周水肿程度以及血清VEGF水平的变化。 \u0000 \u0000 \u0000结果 \u0000治疗后19例患者症状明显减轻，6例患者症状改善不明显；所有患者KPS评分高于治疗前，瘤周水肿指数较治疗前下降，差异均具有统计学意义（均P<0.05）。治疗后血清VEGF水平较治疗前降低，且联用贝伐珠单抗组血清VEGF水平低于单用贝伐珠单抗组，差异均有统计学意义（均P<0.05）。治疗中出现高血压3例，便血及咯血各1例，经对症处理后好转，无严重不良反应发生。 \u0000 \u0000 \u0000结论 \u0000贝伐珠单抗治疗肺腺癌脑转移伴难治性瘤周水肿具有一定疗效，可以改善患者生命质量，且可有效降低患者血清VEGF水平，提示VEGF有可能成为判断疗效及疾病进展的重要指标之一。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"49-52"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42923106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy combined with R0 resection for treatment of pulmonary sarcomatoid carcinoma: report of one case and review of literature","authors":"Shu-dong Yang, Weifei Fan","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.012","url":null,"abstract":"目的 \u0000探讨肺肉瘤样癌（PSC）新辅助化疗对患者手术的影响。 \u0000 \u0000 \u0000方法 \u0000回顾性分析南京医科大学附属老年医院收治的1例PSC（cT3NxM0）患者的临床资料、病理特点和治疗方案，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000该患者接受2个周期新辅助化疗后，肺部原发灶退缩明显，获得手术切除机会，实现R0切除。术后病理分期为ypT1N0M0 ⅠA期。 \u0000 \u0000 \u0000结论 \u0000PSC预后差，手术切除是最重要的治疗模式。早期患者建议采用新辅助化疗联合手术切除，或手术切除联合辅助化疗方式治疗。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"55-57"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44118506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of prognostic prediction model of resectable lung cancer and survival analysis","authors":"Yunkui Zhang, R. Zhang, S. Peng","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.004","url":null,"abstract":"Objective \u0000To explore the value of the constructed prognostic prediction model of resectable lung cancer in predicting the survival and prognosis of patients. \u0000 \u0000 \u0000Methods \u0000A total of 2 267 patients with primary lung cancer in Shanxi Provincial Cancer Hospital from January 2007 to September 2018 were selected. All patients underwent primary lung cancer surgery without a second primary tumor. Gender, age, occupation, tumor site, pathological type, surgical path, surgical method, tumor stage and treatment were selected as the prognostic factors. A Cox proportional hazard model was used to construct a prognostic index (PI) equation to calculate the PI value of each patient. According to the different ranges of PI values, the low-, intermediate- and high-risk prognosis groups were divided, and the survival status of three groups were evaluated. \u0000 \u0000 \u0000Results \u0000Gender (RR= 0.684, P= 0.001), age (RR= 0.591, P -0.5 was the high-risk group, and the differences of their survival rates were statistically significant (P < 0.05). The 1-, 3-, and 5-year survival rates for the low-, risk groups were 96.8%, 87.0% and 77.9%; the intermediate-risk group were 91.8%, 82.2% and 61.7%; the high-risk group were 86.5%, 61.7% and 50.3%. respectively. \u0000 \u0000 \u0000Conclusion \u0000The prognostic prediction model of resectable lung cancer can predict the prognosis risk and the corresponding survival rate of patients with resectable lung cancer, and it can help clinicians to evaluate the prognosis and formulate subsequent treatment plans. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Thoracic surgical procedures; Prognosis; Models, genetic; Survival analysis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"16-21"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43567644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of long non-coding RNA in pituitary adenoma","authors":"Jinke Ding, Chenglong Li, H. Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.016","url":null,"abstract":"Pituitary adenoma is a common neuroendocrine tumor, and its complex pathogenesis makes its treatment a clinical problem. Recently, studies have shown that long non-coding RNA (LncRNA), as a class of endogenous RNA with a length of more than 200 nucleotides and basically no protein-coding function, plays an important regulatory role in various forms in multiple tumors including pituitary adenoma, and is closely related to the proliferation, invasion and metastasis of pituitary adenoma. Based on the latest research status at home and abroad, this paper summarizes the research progress of LncRNA in pituitary adenoma, hoping to provide new ideas for the diagnosis, treatment and prognosis of pituitary adenoma. \u0000 \u0000 \u0000Key words: \u0000Neuroendocrine tumors; Brain neoplasms; Long non-coding RNA","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46561984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of gene mutations in Chinese single-center pulmonary adenocarcinoma patients and comparison with European and American pulmonary adenocarcinoma populations","authors":"Yanian Zhang, Wentao Dong, Wenlu Xiao","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.008","url":null,"abstract":"Objective \u0000To explore the characteristics and significances of gene mutations in pulmonary adenocarcinoma, and to provide evidence for targeted medication. \u0000 \u0000 \u0000Methods \u0000High throughput sequencing based target-capture sequencing was performed in 104 patients with pulmonary adenocarcinoma to detect the mutational status of 56 cancer-related genes. All patients were diagnosed in the First People's Hospital of Kunshan from May 2017 to August 2018. The mutational characteristics of pulmonary adenocarcinoma was analyzed and compared with European and American pulmonary adenocarcinoma populations. The correlations between mutational characteristics and clinical features were analyzed, and the mutation sites for targeted medication were screened. \u0000 \u0000 \u0000Results \u0000Among 104 patients with pulmonary adenocarcinoma, totally 34 mutational genes were detected in 84 patients (81%, 84/104). Highly frequent mutations included epidermal growth factor receptor (EGFR) (49%, 51/104), TP53 (21%, 22/104), KRAS (13%, 14/104), and BRAF (6%, 6/104). Among all the 187 variants, 76% (142/187) were non-synonymous missense mutations, 13% (24/187) were small fragment deletions, 6% (12/187) were copy number variants, 3% (5/187) were small fragment insertions, and 2% (4/187) were nonsense site mutations. Among 104 patients with pulmonary adenocarcinoma, 34 targeted drug-associated mutations of 13 genes were detected in 68 patients (65%), and 19 (18%) patients harbored ≥ 2 targeted drug-associated mutations. EGFR mutations were more common in female patients than in male patients [62% (34/55)vs. 35% (17/49), χ2= 7.629, P= 0.006], while KRAS mutations were more frequent in male patients than in female patients [22% (11/49) vs. 5% (3/55), χ2= 6.424, P= 0.011]. The mutation frequencies of gene EGFR, TP53, KRAS, and CDKN2A in Chinese single-center (the First People's Hospital of Kunshan) and European and American adenocarcinoma populations were significantly different (all P < 0.05). \u0000 \u0000 \u0000Conclusions \u0000The molecular mutational characteristics of pulmonary adenocarcinoma are complex, and vary greatly among different populations. High throughput sequencing-based multiple-gene detection can reveal its mutational features comprehensively, and that has important roles in personal targeted medication guidance, drug-resistance monitoring and prognosis evaluation. \u0000 \u0000 \u0000Key words: \u0000Lung neoplasms; Adenocarcinoma; High-throughput nucleotide sequencing; Mutation; Molecular targeted therapy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"36-41"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48038388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of thoracoscopic bronchial sleeve lobectomy for central non-small cell lung cancer","authors":"Shuangping Zhang, Shi-ping Guo, Jianhong Lian, Yong Ma","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.006","url":null,"abstract":"Objective \u0000To explore the efficacy of thoracoscopic bronchial sleeve lobectomy for central non-small cell lung cancer (NSCLC), and to evaluate the safety of this operation. \u0000 \u0000 \u0000Methods \u0000The clinical data of 29 patients who underwent thoracoscopic bronchial sleeve lobectomy at Shanxi Provincial Cancer Hospital from May 2015 to September 2018 were retrospectively analyzed, and the surgical effect and safety were analyzed. \u0000 \u0000 \u0000Results \u0000Twenty-nine cases underwent thoracoscopic bronchial sleeve lobectomy. The types of resection included 13 cases of right upper, 10 cases of left upper, and 6 cases of left lower sleeve lobectomy. The operation time was 180-400 min, and the median time was 240 min. The bronchial anastomosis time was 35-60 min, and the median time was 48 min. The intraoperative blood loss was 150-460 ml, and the median blood loss was 220 ml. The number of lymph node dissection was 12-39 lymph nodes per patient, with a median of 19.6 lymph nodes per patient. The thoracic drainage tube was placed for 4-16 days after operation, with a median of 6 days; the postoperative hospital stay was 6-16 days, with a median of 9 days. The postoperative complication rate was 24.1% (7/29), including 1 case with pulmonary air leakage (> 7 days), 2 cases with pulmonary infections, 3 cases with arrhythmia, and 1 patient discharged from the hospital on the 7th day after surgery, but died of anastomotic fistula bleeding on the 40th day. The rest of the patients recovered smoothly after surgery. The median follow-up time was 6 months (3-12 months). No tumor recurrence or anastomotic stenosis was observed. \u0000 \u0000 \u0000Conclusion \u0000Thoracoscopic bronchial sleeve lobectomy is a safe and feasible surgical treatment for central NSCLC. \u0000 \u0000 \u0000Key words: \u0000Carcinoma, non-small-cell lung; Thoracoscopes; Sleeve lobectomy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42715450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of epidural anesthesia with paravertebral nerve block for non-intubated uniportal video-assisted thoraeoseopic surgery","authors":"Panpan Li, X. Lang","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.011","url":null,"abstract":"目的 \u0000比较硬膜外麻醉与椎旁神经阻滞非气管插管单孔胸腔镜手术的效果。 \u0000 \u0000 \u0000方法 \u0000选择2017年11月至2019年6月锦州医科大学附属第一医院收治的45例采用非气管插管麻醉单孔胸腔镜手术的肺部良恶性肿瘤患者，采用随机数字表法分为椎旁神经阻滞组（22例）与硬膜外麻醉组（23例）。麻醉诱导前，椎旁神经阻滞组均于超声引导下阻滞胸3~6棘突旁神经根；硬膜外麻醉组均于胸6~7或7~8间隙行硬膜外穿刺置管麻醉。比较两组手术时间、术中出血量、术后定向力恢复时间、下床活动时间、带管时间、出院时间及相关并发症。 \u0000 \u0000 \u0000结果 \u0000两组患者手术时间、术中出血量差异均无统计学意义（均P>0.05）。与硬膜外麻醉组相比，椎旁神经阻滞组术后定向力恢复时间[（7.22±2.20）min比（18.80±5.06）min]、下床活动时间[（11.45±3.01）h比（21.90±4.61）h]、带管时间[（2.77±0.81）d比（5.47±1.31）d]、出院时间[（3.68±0.84）d比（6.17±1.03）d]均缩短，两组差异均有统计学意义（t值分别为-9.874、-8.763、-8.282、-7.594，均P<0.05）。椎旁神经阻滞组术后未发生低氧血症、低血压、肺部并发症、恶心、呕吐、尿潴留等相关并发症。 \u0000 \u0000 \u0000结论 \u0000非气管插管单孔胸腔镜手术中采用椎旁神经阻滞术后恢复快、并发症少，临床上可优先选择，有助于快速康复。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"52-55"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48387789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-guided versus ultrasound-guided percutaneous lung puncture biopsy in the diagnosis of peripheral pulmonary masses: a Meta-analysis","authors":"Meng Hu, Jing Liu, Weirong Yao, Xiquan Zhang, Zhiyong Zhou, Lin Zeng","doi":"10.3760/CMA.J.ISSN.1006-9801.2020.01.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2020.01.009","url":null,"abstract":"Objective \u0000To systematically evaluate the efficacy and safety of CT-guided percutaneous lung puncture biopsy versus ultrasound-guided percutaneous lung puncture biopsy. \u0000 \u0000 \u0000Methods \u0000Relevant domestic and foreign related databases such as PubMed, Web of Science, Cochrane Library, OVID, China Biology Medicine, VIP, Wanfang and CNKI databases were searched, the randomized controlled trial about the applications of CT-guided and ultrasound-guided percutaneous lung puncture biopsy were collected. After extracting the relevant data, a Meta-analysis was performed using RevMan 5.2 and Stata softwares. \u0000 \u0000 \u0000Results \u0000Ten studies met the inclusion criteria, with a total sample size of 1 158 cases, of which 635 were CT-guided puncture biopsy and 523 were ultrasound-guided puncture biopsy. Meta-analysis showed that the difference of the success rate between the CT-guided group and the ultrasound-guided group was not statistically significant [97.48% (619/635) vs. 96.56% (505/523), RR= 1.01, 95% CI 0.99-1.03, P= 0.360]; the puncture diagnosis rate in the CT-guided group was lower than in the ultrasound-guided group, and the difference was statistically significant [92.44% (619/635) vs. 96.56% (505/523), RR= 0.97, 95% CI 0.94-0.99, P= 0.007]. The total incidence of complications after puncture in the CT-guided group was higher than that in the ultrasound-guided group, and the difference was statistically significant [14.49% (92/635) vs. 9.56% (50/523), RR= 1.56, 95% CI 1.11-2.19, P= 0.010]; the incidence of pneumothorax after puncture in the CT-guided group was higher than that in the ultrasound-guided group, and the difference was statistically significant [11.50%(73/635) vs. 6.31% (33/523), RR= 1.77, 95% CI 1.17-2.68, P= 0.007]; the difference of the incidence of bleeding after puncture between the CT-guided group and the ultrasound-guided group was not statistically significant [2.99% (19/635) vs. 3.25% (17/523), RR= 1.08, 95% CI 0.59-1.98, P= 0.800]. \u0000 \u0000 \u0000Conclusions \u0000Both CT-guided and ultrasound-guided percutaneous lung puncture biopsy have good clinical diagnostic value. However, for the intrapulmonary masses shown by ultrasound, the ultrasound-guided lung puncture biopsy has a shorter operation time, lower cost, and higher safety. \u0000 \u0000 \u0000Key words: \u0000Biopsy; Punctures; Ultrasonogrophy; Computed tomography; Peripheral pulmonary masses; Meta-analysis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"42-48"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48077103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}